While the role for CDKN2A and TP53 are integral to oncogenesis of melanoma and escape from senescence these mutations do not appear to have a significant deleterious effect on prognosis when immune checkpoint inhibitors are used for therapy. The gene discussed is CDKN2A; the disease is melanoma.